Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

RINVOQ 30 mg prolonged-release tablets {equilateral_black_triangle}

Active Ingredient:
upadacitinib hemihydrate
Company:  
AbbVie Ltd See contact details
ATC code: 
L04AA44
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Letters to HCPs HCP Med Info
{arrow_left}
{arrow_right}
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine.
{info_black}
Last updated on emc: 21 Dec 2023

{equilateral_black_triangle} This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

{pdf} View or print the patient leaflet as PDF
AbbVie Ltd
Company image
Address
AbbVie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, SL6 4UB, UK
WWW
www.abbviemedinfo.com
WWW
www.abbvie.co.uk
Telephone
+44 (0)1628 561 092
Medical Information e-mail
[email protected]
Out of Hours Telephone
+44 (0)1628 561 092